The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS
Abstract
SUMMARY: The clinical properties (efficacy and safety profile) of a medicine are related not only to its mode of action, but also to its selectivity for its target (usually a receptor or enzyme) and are also influenced by its pharmacokinetic properties (absorption, distribution, metabolism and elimination). The growing number of phosphodiesterase inhibitors that are selective for phosphodiesterase‐5 (PDE5) represent a promising new class of compounds that are useful for the treatment of erectile dysfunction and perhaps other disorders. Some of the basic pharmacodynamic and pharmacokinetic parameters that describe drug action are discussed with regard to the new PDE5 inhibitors. Central topics reviewed are the concentration that produces a given in vitro response, or potency (IC 50), maximum plasma concentration (C max), time to C max (T max), half‐life (t ½), area under the curve (AUC), bioavailability, onset and duration of action, and the balance to achieve optimum safety and efficacy. To illustrate these concepts, a group of inhibitors with varying selectivities and potencies for PDE5 (theophylline, IBMX, zaprinast, sildenafil, tadalafil and vardenafil) are discussed. Each drug has its own set of unique pharmacological characteristics based on its specific molecular structure, enzyme inhibition profile and pharmacokinetic properties. Each PDE5 inhibitor has a distinct selectivity that contributes to its safety profile. As with all new drugs, and especially those in a new class, careful evaluation will be necessary to ensure the optimal use of the PDE5 inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms
Beavo, J. A. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.4.725 · Cited by 1,767
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C., & Long, G. W. (1991) · JAMA · doi:10.1001/jama.1991.03460200114048 · Cited by 1,063
Beavo, J. A., & Reifsnyder, D. H. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90066-h · Cited by 849
BALLARD, S. A., GINGELL, C. J., TANG, K., TURNER, L. A., PRICE, M. E., & NAYLOR, A. M. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63299-3 · Cited by 591
Cyclic nucleotide phosphodiesterases: Relating structure and function
Francis, S. H., Turko, I. V., & Corbin, J. D. (2000) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(00)65001-8 · Cited by 570
Self-citationCyclic GMP Phosphodiesterase-5: Target of Sildenafil
Corbin, J. D., & Francis, S. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13729 · Cited by 536
Self-citationWallis, R. M., Corbin, J. D., Francis, S. H., & Ellis, P. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00042-9 · Cited by 501
Self-citationMolecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
Fawcett, L., Baxendale, R. W., Stacey, P., McGrouther, C., Harrow, I., Soderling, S. H., Hetman, J., Beavo, J. A., & Phillips, S. C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3702 · Cited by 380
Nichols, D. J., Muirhead, G. J., & Harness, J. A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.00027.x · Cited by 358
Research works printed but not linked: 9
- Boolell M, 1996, Sildenafil: an orally active type 5 cyclic GMP‐specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int, J Impot Res, 8, 47
- Murray KJ, 1993, Phosphodiesterase V inhibitors, Drug News Perspect, 6, 150
- Patterson B, 2001, The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351), Int J Impot Res, 13, S63
- Angulo J, 2001, IC351 enhances nitric oxide‐mediated relaxation of human arterial and trabecular penile smooth muscle, Diabetologia, 44, A295
- Baxendale RW, 2001, Selectivity of sildenafil citrate and other phosphodiesterase type 5 (PDE5) inhibitors against human phosphodiesterase types 7–11, J Clin Pharmacol, 41, 1015
- Baxendale R, 2000, Human PDE11: a distinct, dual‐substrate phosphodiesterase expressed in vascular smooth muscle and cardiac myocytes, Circulation, 102, 320
- 1999, Viagra® [package insert]
- Patterson B, 2001, Dose‐normalized pharmacokinetics of single dose tadalafil (IC351) in healthy volunteers, Int J Impot Res, 13, S63
- Padma‐Nathan H, 2001, Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction, J Urol, 165, 224
Cited by
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2030 · Cited by 629
Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases
Card, G. L., England, B. P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C. A., Tabrizizad, M., Gillette, S., Ibrahim, P. N., et al. (2004) · Structure · doi:10.1016/j.str.2004.10.004 · Cited by 454
Function of cGMP-Dependent Protein Kinases as Revealed by Gene Deletion
Hofmann, F. B., Feil, R., Kleppisch, T., & Schlossmann, J. (2005) · Physiological Reviews · doi:10.1152/physrev.00015.2005 · Cited by 403
McVary, K. T., Wb, M., Camps, J. L., Young, J. M., Tseng, L., & Ende, G. V. D. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.10.055 · Cited by 352
Puzzo, D., Staniszewski, A., Deng, S., Privitera, L., Leznik, E., Liu, S., Zhang, H., Feng, Y., Palmeri, A., Landry, D. W., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0864-09.2009 · Cited by 338
Metadata
- Authors
- Corbin, J., & Francis, S.
- Affiliations
- Department of Molecular Physiology and Biophysics Vanderbilt University School of Medicine Nashville Tennessee USA
- Venue
- International Journal of Clinical Practice
- Publisher
- Wiley
- Published
- 2002-07
- Volume
- 56
- Issue
- 6
- Pages
- 453-459
- ISSN
- 1368-5031 (ISSN-L)
- 1742-1241
- OpenAlex
- W4367480699
- Cited by
- 260
- References
- 43
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 6 · 2019: 7 · 2018: 3 · 2017: 9 · 2016: 9 · 2015: 5 · 2014: 12 · 2013: 12 · 2012: 13
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Clinical Practice (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- phosphodiesterase-5 inhibitors, sildenafil, tadalafil, vardenafil, zaprinast, theophylline, 3-isobutyl-1-methylxanthine, pharmacokinetics, pharmacodynamics, enzyme selectivity, potency, bioavailability, erectile dysfunction, drug safety, drug efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS. https://app.cochat.ai/papers/10.1111/j.1742-1241.2002.tb11296.x
- The paper
- Corbin, J., & Francis, S. (2002). PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2002.tb11296.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
